08:24 uur 31-03-2021

Rapid Medical krijgt goedkeuring van de FDA voor de eerste verstelbare stentretriever voor gebruik bij de behandeling van ischemische beroertes

TIGERTRIEVER™ maakt gebruik van de gepatenteerde technologie van Rapid Medical om de effectiviteit van minimaal invasieve verwijdering van stolsels in de hersenen aanzienlijk te verbeteren

YOKNEAM, Israel & MIAMI– (BUSINESS WIRE) – Rapid Medical, ontwikkelaar van responsieve, instelbare neurovasculaire apparaten, kondigt de goedkeuring door de FDA aan van zijn TIGERTRIEVER ™ revascularisatie-apparaat voor gebruik bij de behandeling van ischemische beroerte. TIGERTRIEVER is de eerste stentretriever die intelligente controle biedt, waardoor neuro-interventionalisten bloedstolsels beter kunnen verwijderen en de bloedstroom in de hersenen kunnen herstellen na een ischemische gebeurtenis – een aandoening die jaarlijks 800.000 Amerikanen verwoest. Al goedgekeurd in Europa, zijn meer dan 5.000 patiënten behandeld met TIGERTRIEVER.

Ronen Eckhouse, medeoprichter en CEO van Rapid Medical zegt: “De FDA-goedkeuring van TIGERTRIEVER is een belangrijke mijlpaal in de ontwikkeling en groei van Rapid’s wereldwijde activiteiten. Het is een geweldig bewijs van de voordelen van onze gepatenteerde 3D-vlechttechnologie: het platform voor ons portfolio van op afstand verstelbare neurovasculaire apparaten, waaronder de producten van Comaneci en Columbus.”

Rapid Medical Receives FDA Clearance for the First Adjustable Stent Retriever for Use in Ischemic Stroke Treatment

TIGERTRIEVER™ uses Rapid Medical’s proprietary technology to significantly improve the effectiveness of minimally invasive clot removal in the brain

YOKNEAM, Israel & MIAMI–(BUSINESS WIRE)– Rapid Medical, developer of responsive, adjustable neurovascular devices, announces the FDA clearance of its TIGERTRIEVER™ revascularization device for use in the treatment of ischemic stroke. TIGERTRIEVER is the first stent retriever to offer intelligent control, enabling neuro interventionalists to better remove blood clots and restore blood flow the brain following an ischemic event—a condition that devastates 800,000 Americans annually. Already approved in Europe, over 5,000 patients have been treated with TIGERTRIEVER.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210325005722/en/

Rapid Medical's TIGERTRIEVER provides a better grip on clots during stroke treatment, as shown by the pivotal TIGER Trial. (Photo: Business Wire)

Rapid Medical’s TIGERTRIEVER provides a better grip on clots during stroke treatment, as shown by the pivotal TIGER Trial. (Photo: Business Wire)

Ronen Eckhouse, Rapid Medical Co-founder and CEO states, “The FDA clearance of TIGERTRIEVER is a significant milestone in the development and growth of Rapid’s global business. It is a great testament to the advantages of our proprietary 3D braiding technology–the platform for our portfolio of remotely adjustable neurovascular devices, including the Comaneci and Columbus products.”

Existing stent retrievers are non-adjustable, passive devices, delivered to the occlusion minimally invasively through the vasculature. When unconfined, they slowly expand into the blood clot. The blockage is hopefully captured and removed as the device is retrieved. Though currently recognized as the gold standard in treating large vessel ischemic stroke, traditional stent retrievers have significant limitations. They cannot be adjusted for patient variability and fail in about 30% of revascularization procedures.

TIGERTRIEVER provides physicians with intelligent control during thrombectomy procedures. With full device visibility and adjustability, physicians adapt their approach to visual and tactile feedback as needed. The benefit of this tailored approach to ischemic stroke patients was proven in the recently published TIGER Trial.

The TIGER Trial is a 160-patient pivotal trial to support FDA clearance, performed at 16 US Stroke Centers and 1 Israeli hospital. The study documents TIGERTRIEVER’s superiority over conventional stent retrievers, achieving a statistically significant improvement in the ability to restore blood flow to the brain and excellent comparable safety metrics. The trial also reveals the lowest-ever rate of clot fragmentation, suggesting that TIGERTREIVER’s control may provide better retention of the entire clot and minimize the potential for additional strokes caused by embolic particles.

“In the TIGER Trial, we saw an 11-point improvement in revascularization with TIGERTRIEVER over the data from recent stent retriever trials. This may improve outcomes for 1 in 10 stroke patients, a major leap from previous devices,” stated Dr. Rishi Gupta, national co-principal investigator of the TIGER Trial, vascular neurologist and Director of Neurocritical Care at WellStar Health System in Marietta, GA. “I have more control over the clot when I need it,” added Dr. Gupta.

TIGERTRIEVER is available in the USA in 21 mm and 17 mm sizes, applicable for a wide range large vessel occlusions.

About Rapid Medical

Rapid Medical develops the premier responsive interventional devices for neurovascular diseases such as ischemic and hemorrhagic stroke. Utilizing novel manufacturing techniques, Rapid Medical’s products are remotely adjustable and fully visible. This enables physicians to respond in real-time to the intravascular environment and have greater control over procedural outcomes. TIGERTRIEVER™, COMANECI™ and COLUMBUS™/DRIVEWIRE are CE marked. COMANECI™ and DRIVEWIRE are also FDA approved. More information is available at www.rapid-medical.com.


Ronen Eckhouse



Check out our twitter: @NewsNovumpr